At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Apr 10, 2026 at 08:30 ET
Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but secured $10M in gross proceeds from a public offering, extending its cash runway to Q2 2027 and fully funding its path to a Phase 3 Alzheimer's data readout and NDA submission for buntanetap.
- Reported EPS of $-0.39, missing consensus by $-0.03 (-8.3%)
- No revenue reported for the period
- Closed $10M underwritten public offering, extending cash runway to Q2 2027
- Alzheimer's Phase 3 trial 75% enrolled; 6-month symptomatic data readout expected Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access